Research into the clinical use of a recombinant form of human Activated Protein C (rhAPC) known as Drotrecogin alfa-activated, branded Xigris by Eli Lilly and Company, has been surrounded by controversy.
As investigacións sobre o uso clínico dunha forma recombinante da proteína C activada (rhAPC) chamada Drotrecogin alfa activada, comercializada como Xigris pola compañía Eli Lilly and Company, estiveron rodeadas de bastante controversia.